(Q49161794)

English

Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.

scientific article published on 27 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Mycobacterium tuberculosis

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Frédéric Clement

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Opokua Ofori-Anyinam

10

object named as

Opokua Ofori-Anyinam

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Isabel Leroux-Roels

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Sheron Forgus

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Fien De Boever

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Marie-Ange Demoitié

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Pascal Mettens

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Philippe Moris

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Edouard Ledent

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Geert Leroux-Roels

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M72 Study Group

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

0 references

publication date

27 May 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2196-2206

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22643213%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Tuberculosis vaccines: beyond bacille Calmette-Guerin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Vaccines against intracellular infections requiring cellular immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Targeting the innate immune response with improved vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Monophosphoryl lipid A activates both human dendritic cells and T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Tuberculosis vaccine development; from mouse to man.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Quality and Vaccine Efficacy of CD4+ T Cell Responses Directed to Dominant and Subdominant Epitopes in ESAT-6 from Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

TNF-alpha in tuberculosis: a cytokine with a split personality

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Immunological biomarkers of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Direct access to CD4+ T cells specific for defined antigens according to CD154 expression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Antigen-specific central memory CD4+ T lymphocytes produce multiple cytokines and proliferate in vivo in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Depressed CD40 ligand expression contributes to reduced gamma interferon production in human tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

The effect of bacille Calmette-Guérin vaccine strain and route of administration on induced immune responses in vaccinated infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Dynamic relationship between IFN-gamma and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

A comparison of IFNgamma detection methods used in tuberculosis vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8+ T cell response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

NK cells as effectors of acquired immune responses: effector CD4+ T cell-dependent activation of NK cells following vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

The protective role of antibody responses during Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.035

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49161794&oldid=1402412673"